Sun Pharma slumps after $550 mln patent suit settlement with Pfizer

MUMBAI (Reuters) - Shares in Sun Pharmaceutical Industries more than 5 percent after the company settled a patent suit with Pfizer Inc related to its acid-reflux drug for $550 million.

Credit Suisse said in a report it was surprised with both the timing and amount of the settlement and expects Sun's management to be more conservative in future "at-risk" generic drug launches. (Reporting by Abhishek Vishnoi; Editing by Prateek Chatterjee)